Patent · US Active

Diagnosis, prognosis and treatment of a disease related to a decrease of F. prausnitzii

US12405267B2 · kind B2 · utility

0Cited by
0References
3Claims
0Family size

Assignees

Inventors

Key dates

Filing dateMay 31, 2019
Grant dateSep 2, 2025
Priority date
Expiry dateJan 5, 2043

Classification

  • Technology area (CPC G)Physics
  • CPC primaryG01N2800/56
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The invention relates to a method comprising a step of determining the number, concentration and/or proportion of T lymphocytes with a CD4+ CD8ααlow phenotype and further expressing CCR6 and/or CXCR6, for (i) diagnosing, (ii) prognosing outcome of, or (iii) predicting the risk of developing a disease related to a decrease of F. prau. The invention also concerns the treatment of said disease by administering a population of these specific T lymphocytes. The Inventors have indeed identified two markers, CCR6 and CXCR6, enabling to select a population of F. prau-specific cells among CD4+ CD8ααlow T lymphocytes, from a blood sample and without needing to assess their F. prau specificity. T lymphocytes with a CD4+ CD8ααlow CCR6+ CXCR6+ phenotype are for example significantly decreased in IBD patients. The disease related to a decrease of F. prau is particularly an inflammatory bowel disease (IBD), such as Crohn's disease.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.